Biomarqueurs tumoraux circulants

Publications

Année de publication : 2018

François-Clément Bidard, Stefan Michiels, Sabine Riethdorf, Volkmar Mueller, Laura J Esserman, Anthony Lucci, Bjørn Naume, Jun Horiguchi, Rafael Gisbert-Criado, Stefan Sleijfer, Masakazu Toi, Jose A Garcia-Saenz, Andreas Hartkopf, Daniele Generali, Françoise Rothé, Jeffrey Smerage, Laura Muinelo-Romay, Justin Stebbing, Patrice Viens, Mark Jesus M Magbanua, Carolyn S Hall, Olav Engebraaten, Daisuke Takata, José Vidal-Martínez, Wendy Onstenk, Noriyoshi Fujisawa, Eduardo Diaz-Rubio, Florin-Andrei Taran, Maria Rosa Cappelletti, Michail Ignatiadis, Charlotte Proudhon, Denise M Wolf, Jessica B Bauldry, Elin Borgen, Rin Nagaoka, Vicente Carañana, Jaco Kraan, Marisa Maestro, Sara Yvonne Brucker, Karsten Weber, Fabien Reyal, Dominic Amara, Mandar G Karhade, Randi R Mathiesen, Hideaki Tokiniwa, Antonio Llombart-Cussac, Alessandra Meddis, Paul Blanche, Koenraad d'Hollander, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Klaus Pantel (2018 Apr 17)

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Journal of the National Cancer Institute : DOI : 10.1093/jnci/djy018 En savoir plus
Résumé

We conducted a meta-analysis in nonmetastatic breast cancer patients treated by neoadjuvant chemotherapy (NCT) to assess the clinical validity of circulating tumor cell (CTC) detection as a prognostic marker.

Replier

Année de publication : 2017

G Beinse, F Berger, P Cottu, M-E Dujaric, I Kriegel, M-N Guilhaume, V Diéras, L Cabel, J-Y Pierga, F-C Bidard (2017 Aug 6)

Circulating tumor cell count and thrombosis in metastatic breast cancer.

Journal of thrombosis and haemostasis : JTH : 1981-1988 : DOI : 10.1111/jth.13792 En savoir plus
Résumé

Essentials Tumor cells circulating in blood (CTC) may favor thrombotic events in cancer patients. We assessed the impact of CTC on the risk of thrombosis in metastatic breast cancer. Baseline CTC detection was the only independent factor associated with the risk of thrombosis. CTC detection under therapy may be the hidden link between tumor progression & thrombosis.

Replier

Année de publication : 2016

H Bonnefoi, T Grellety, O Tredan, M Saghatchian, F Dalenc, A Mailliez, T L'Haridon, P Cottu, S Abadie-Lacourtoisie, B You, M Mousseau, J Dauba, F Del Piano, I Desmoulins, F Coussy, N Madranges, J Grenier, F C Bidard, C Proudhon, G MacGrogan, C Orsini, M Pulido, A Gonçalves (2016 Apr 8)

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).

Annals of oncology : official journal of the European Society for Medical Oncology / ESMO : 812-8 : DOI : 10.1093/annonc/mdw067 En savoir plus
Résumé

Several expression array studies identified molecular apocrine breast cancer (BC) as a subtype that expresses androgen receptor (AR) but not estrogen receptor α. We carried out a multicentre single-arm phase II trial in women with AR-positive, estrogen, progesterone receptor and HER2-negative (triple-negative) metastatic or inoperable locally advanced BC to assess the efficacy and safety of abiraterone acetate (AA) plus prednisone.

Replier
François Bertucci, Mahmoud Fekih, Aurélie Autret, Thierry Petit, Florence Dalenc, Christelle Levy, Gilles Romieu, Jacques Bonneterre, Jean-Marc Ferrero, Pierre Kerbrat, Patrick Soulie, Marie-Ange Mouret-Reynier, Thomas Bachelot, Florence Lerebours, Jean-Christophe Eymard, Mathilde Deblock, Alain Lortholary, Anne-Claire Hardy-Bessard, Philippe Barthelemy, Hervé Bonnefoi, Emmanuelle Charafe-Jauffret, François-Clément Bidard, Patrice Viens, Jérôme Lemonnier, Jean-Yves Pierga (2016 Apr 2)

Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.

The Lancet. Oncology : DOI : S1470-2045(16)00011-5 En savoir plus
Résumé

Addition of bevacizumab to standard chemotherapy in the neoadjuvant setting in patients with HER2-negative metastatic breast cancer improves progression-free survival and the proportion of patients achieving pathological complete response. In the BEVERLY-1 (UCBG-0802) trial we aimed to assess the addition of bevacizumab to neoadjuvant and adjuvant chemotherapy in the treatment of patients with HER2-negative inflammatory breast cancer.

Replier